United-Guardian(US:UG)2024-11-08 14:00Sales Performance - Sales for the nine-month period increased from $8,278,141 in 2023 to $9,705,262 in 2024, representing a growth of 17.2%[1] - Third quarter sales remained steady at $3,060,113 in 2024 compared to $3,057,518 in 2023, with net income increasing from $626,756 ($0.14 per share) to $865,484 ($0.19 per share), a growth of 38.1%[1] - Sales of cosmetic ingredients increased by 8% in the third quarter and 68% in the first nine months of 2024 compared to the same periods in 2023[2] - Medical lubricants sales decreased by 2% in the third quarter but increased by 4% in the first nine months of 2024 compared to 2023[2] - Pharmaceutical product sales decreased by 6% in the third quarter and 11% for the nine-month period, attributed to a supply disruption[2] - The company expects sales to continue increasing as it recovers from the supply limitations of its key pharmaceutical product, Renacidin[2] Income and Expenses - Net income for the nine-month period rose from $1,843,931 ($0.40 per share) in 2023 to $2,747,151 ($0.60 per share) in 2024, an increase of 48.9%[1] - Total costs and expenses for the nine-month period were $6,614,849 in 2024, up from $6,206,375 in 2023, reflecting an increase of 6.6%[4] - Income from operations for the nine-month period increased from $2,071,766 in 2023 to $3,090,413 in 2024, a growth of 49.2%[4] - Total other income for the nine-month period rose from $248,087 in 2023 to $377,232 in 2024, an increase of 52.0%[4]